BioSpace News Archive

Funding will accelerate commercialization of Gemelli’s trio-smart ® and ibs-smart ® precision diagnostic tests for IBS and SIBO, and its strategies for gastrointestinal discoveries related to the microbiome.

Schrödinger, Inc . (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today will host its second annual Educator’s Day , bringing together K-12 and university educators from across the globe to discuss the growing opportunity for incorporating computational tools in the classroom.

Cyclerion Therapeutics, Inc. will participate in a webinar hosted by the United Mitochondrial Disease Foundation (UMDF) on Tuesday, June 28th at 8 a.m. EDT with a live Q&A.

Global Life Sciences Industry Executive Transitions from Interim CEO Role to Full-Time Leadership Position to Lead Commercialization of Disruptive Diagnostic Technology.

Sanofi is pleased to announce the opening of an Artificial Intelligence Centre of Excellence in Toronto, joining Sanofi’s global network of existing digital hubs in Paris, Boston, New York and Barcelona.

Mycovia Pharmaceuticals, Inc. today shared topline results from evaluating VIVJOA™ (oteseconazole) capsules in patients suffering from recurrent vulvovaginal candidiasis (RVVC).

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Anne Frese, an experienced industry executive, joined MEI as chief people officer, a role reporting to Daniel P. Gold, chief executive officer.

Zebra Technologies Corporation, an innovator at the front line of business with solutions and partners that deliver a performance edge, announced the ET4x-HC series, including the Android™-based ET40-HC and ET45-HC tablets, built to improve staff efficiency, care quality and the patient experience.

Nutcracker Therapeutics reveals oncology-focused pipeline programs, with lead candidate in IND-enabling studies.

Nucleix Expands EU Label Indication of Bladder EpiCheck ® to Include the Detection of Primary Bladder Cancer and Detection of Primary and Recurrent Upper Tract Urinary Cancer.